tbuckley/cabot-search huggingface dataset:
SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors
Authors: Pooja Panwalkar, Drew Pratt, Chan Chung, Derek Dang, Paul Le, Daniel Martinez, Jill M Bayliss, Kyle S Smith, Mike Adam, Steven Potter, Paul A Northcott, Leo Mascarenhas, Jared Shows, Bruce Pawel, Ashley Margol, Annie Huang, Alexander R Judkins, Sriram Venneti
Journal: Neuro-Oncology (2020)

Rhabdoid tumors (RTs) arise within (atypical teratoid/rhabdoid tumor [AT/RT]) or outside the brain (extra [e]CNS-RT) and are driven mainly by inactivation of the SWItch/sucrose nonfermentable (SWI/SNF) complex subunit SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1). A pathognomonic hallmark of RTs is heterogeneous multilineage differentiation, including anomalous neuronal differentiation in some eCNS-RTs. Because remodeling of the SWI/SNF complex regulates differentiation, we hypothesized that SWI/SNF Brahma-associated factors (BAF) and polybromo-associated BAF (PBAF) complex heterogeneity are related to both multilineage differentiation and clinical outcome.We performed an integrated analysis of SWI/SNF complex alterations in the developing kidney and cerebellum (most common regions of RT origin) in comparison to eCNS-RT (n = 14) and AT/RT (n = 25) tumors. RT samples were interrogated using immunohistochemistry, DNA methylation, and gene expression analyses.The SWI/SNF BAF paralogs actin-like protein (ACTL)6A and ACTL6B were expressed in a mutually exclusive manner in the developing cerebellum and kidney. In contrast, a subset of eCNS-RTs lost mutual exclusivity and coexpressed both subunits. These tumors showed aberrant DNA methylation of genes that regulate neuronal and renal development and demonstrated immunohistochemical evidence of neuronal differentiation. In addition, low expression of the PBAF subunit polybromo-1 (PBRM1) identified a group of AT/RTs in younger children with better overall prognosis. PBRM1-low AT/RT and eCNS-RTs showed altered DNA methylation and gene expression in immune-related genes. PBRM1 knockdown resulted in lowering immunosuppressive cytokines, and PBRM1 levels in tumor samples showed an inverse relationship with cluster of differentiation (CD)8 cytotoxic T-cell infiltration.Heterogeneity in SWI/SNF BAF (ACTL6A/ACTL6B) and PBAF (PBRM1) subunits is related to histogenesis, contributes to the immune microenvironment and prognosis in RTs, and may inform opportunities to develop immunotherapies.
Mitophagy Plays a Key Role in the Anti-Leukemic Activity of Autophagy Inhibitors Under Hypoxia in Acute Myeloid Leukemia
Authors: Hannah R.S. Fay, Kaitlyn M. Dykstra, Matthew Johnson, Tara L. Cronin, Linda Lutgen-Dunckley, Brandon L. Martens, Joseph R. Moberg, Monica L. Guzman, Eunice S. Wang
Journal: Blood (2019)
EXTH-30. PRECEDING p53 STABILIZATION USING DOXORUBICIN AUGMENTS PRIMA-1-MEDIATED p53 REFOLDING AND INCREASED CELLULAR APOPTOSIS: EVALUATION OF A SEQUENTIAL COMBINATION THERAPY AGAINST GLIOBLASTOMA
Authors: Husam Babikir, Rayhaneh Afjei, Ramasamy Paulmurugan, Tarik Massoud
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Mutant p53 cancer cells are poorly responsive to chemotherapy. A small molecule drug, PRIMA-1, can bind to wildtype and mutant p53 to induce structural conformation that enhances p53 DNA binding. In a quest for new effective combination chemotherapies, we hypothesized that sequential treatment of GBM cells with doxorubicin then PRIMA-1 could stabilize and refold p53 to enhance chemotherapy-induced cellular apoptosis. We evaluated this combination in GBM cells engineered to express different p53 mutants and exhibiting different phenotypes. METHODS We constructed split reporter biosensors incorporating different structural mutants of p53 (p53Y220C, p53G245S, and p53R282W) all within p53-null Ln308 GBM cells, to evaluate PRIMA-1-mediated refolding of p53 using bioluminescence imaging. We used these cells, and other GBM cells endogenously dissimilar for p53 phenotypes (U87MG with wt-p53, and Ln229 with mutant p53 [mt-p53P98L/p14ARFdel/p16del]), to investigate the anticancer activity of doxorubicin plus PRIMA-1 by using immunoblot analysis of p53 downstream pathway proteins. We also evaluated treatment by imaging mice implanted with GBMs of different p53 phenotypes. RESULTS PRIMA-1 induced reporter complementation at &gt; 80 mM in all GBM cells regardless of p53 status. Doxorubicin stabilized p53 and increased its levels significantly more than in control cells. Significant changes in apoptotic index occurred in GBM cells treated with doxorubicin (1mM) followed by PRIMA-1 (40 mM), compared to cells treated with each drug independently, or with PRIMA-1 followed by doxorubicin. There was upregulation of p53, p21, and Bax, but downregulation of Bcl2 after combination therapy. PRIMA-1 and doxorubicin acted synergistically in GBM cells, but not significantly compared to using doxorubicin followed by PRIMA-1. CONCLUSION Our molecular imaging biosensor is useful to detect drug-induced restoration of p53 wildtype conformation. Doxorubicin stabilizes and increases p53 levels in GBM cells for subsequent enhanced PRIMA-1-mediated p53 refolding and increased levels of cellular apoptosis—an effective anti-GBM combination treatment.
CBMT-23. NON-CANONICAL FUNCTIONS OF TERT IN GLIOBLASTOMA
Authors: Shayesteh Ferdosi, Brett Taylor, Saumya Bollam, Vijay Gokhale, Laurence Hurley, Harshil Dhruv, Michael Berens
Journal: Neuro-Oncology (2019)

Abstract Telomerase is an enzyme with a catalytic subunit, telomerase reverse transcriptase (TERT), that is in charge of telomere elongation in the nucleus. Promotor region of TERT is commonly mutated across cancers, especially in glioblastoma (GBM) with over 80% frequency. In the absence of any effective molecular targeting therapy for GBM, elucidating oncogenic signaling of TERT could open new avenues in GBM treatment. Canonically, mutations of TERT, which result in TERT upregulation, maintain telomere length in the nucleus and promote indefinite proliferation of cancer cells. However, a non-canonical function of TERT in the mitochondria has recently been suggested. We screened GBM cell models against a novel small molecule inhibitor (RG1534, Reglagene Inc.) that interferes with the functionality of a mutated hTERT promoter. RG1534 selectively suppresses glioma cell viability without affecting non-transformed normal human astrocytes. More interestingly, RG1534 treatment leads to rapid apoptosis induction in glioma cell lines that does not correlate with the time course of the telomere shortening effect. We further validated this rapid apoptosis behavior in glioma cell lines using siRNA and CRISPR/Cas-9 mediated hTERT knockdown. We also measured the protein expression of TERT in subcellular fractions of glioma cell lines and demonstrated the presence of higher TERT expression in mitochondrial extract compared to the nucleus. Finally, using MitoSOX dye we assessed ROS generation in glioma cells in response to an oxidant with or without TERT expresssion. In summary, our results demonstrate that non-canonical functions of TERT may play critical role in glioma pathobiology and require more detail investigation.
Reiter's Disease
Authors: K. W. G. Heathfield
Journal: BMJ (1947)

So called "direction" is similarly an outgrowth of the salary idea.The Minister pretends that the aim is a better distribution of doctors, but this is obvious eyewash.The simple fact again is that it is an essential part of a salaried service.A salaried school teacher, salaried dustman, or salaried M.O.H. cannot earn his living as such except where a vacancy in a service occurs.The same would be true of salaried general practitioners.The Minister's real reasons for this objectionable feature, too, therefore evaporate when the salary idea is removed.Let us then keep the salary idea in the forefront of the picture.Let us.if he is persistent, fight the Minister on this issue, which if won can win all, but which if lost mutst lose all.-Iam, etc., West Bromwich, Staffs.D. SAKLATVALA.
Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy
Authors: Hearn Jay Cho, Deepak Perumal, Adeeb H Rahman, Donald Jackson, Michael Robbins, Seunghee Kim-Schultze, Sacha Gnjatic, Samir Parekh, Jonathan J Keats, Daniel Auclair
Journal: Blood (2019)
Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease
Authors: Tianyu Cai, Kathryn L Black, Ammar S. Naqvi, Deanne Taylor, Ming Zhao, Qi Yuan, Mayumi Sugita, Roman Galetto, Agnès Gouble, Julianne N. P. Smith, Antonio Cavazos, Lina Han, Qi Zhang, Vinitha Mary Kuruvilla, Helen Ma, Sergej Konoplev, Guilin Tang, Jun Gu, Xiaoping Su, Sattva S Neelapu, Andrew A. Lane, Hagop M. Kantarjian, Monica L. Guzman, Naveen Pemmaraju, Andrei Thomas-Tikhonenko, Marina Y Konopleva
Journal: Blood (2019)
In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial
Authors: Ashwin Unnikrishnan, Xin Ying Lim, Swapna Joshi, Andrea C. Nunez, Lachlin Vaughan, Russell Pickford, Sally Hough, Sarah Davidson, Chun Fong, Melita Kenealy, Devendra K Hiwase, Leonardo Pasalic, Soma Mohammed, Linda Lee, Freda H. Passam, Kevin Spring, Patricia Rebeiro, Silvia Ling, Stephen Fuller, Peter Presgrave, Fernando Roncolato, Stephen Larsen, Anoop K Enjeti, William S. Stevenson, Campbell Tiley, Peter J Campbell, Charlotte Lemech, Jake Olivier, Mark Hertzberg, Mark N. Polizzotto, John Pimanda
Journal: Blood (2019)
Some Paediatric Problems of Uganda
Authors: G. H. Walker
Journal: BMJ (1957)

Learning is thought to facilitate the recognition of objects by optimizing the tuning of visual neurons to behaviorally relevant features. However, the learning mechanisms that shape neural selectivity for visual forms in the human brain remain essentially unknown. Here, we combine behavioral and functional magnetic resonance imaging (fMRI) measurements to test the mechanisms that mediate enhanced behavioral sensitivity in the discrimination of visual forms after training. In particular, we used high-resolution fMRI and multivoxel pattern classification methods to investigate fine learning-dependent changes in neural preference for global forms. We measured the observers9 choices when discriminating between concentric and radial patterns presented in noise before and after training. Similarly, we measured the choices of a pattern classifier when predicting each stimulus from fMRI activity. Comparing the performance of human observers and classifiers demonstrated that learning alters the observers9 sensitivity to visual forms and the tuning of fMRI activation patterns in visual areas selective for task-relevant features. In particular, training on low-signal stimuli enhanced the amplitude but reduced the width of pattern-based tuning functions in higher dorsal and ventral visual areas. Thus, our findings suggest that learning of visual patterns is implemented by enhancing the response to the preferred stimulus category and reducing the response to nonpreferred stimuli in higher extrastriate visual cortex.
Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo, Irrespective of Prior Treatment with CD20 Monoclonal Antibodies
Authors: Hilma J Van Der Horst, A. Vera de Jonge, Ida H Hiemstra, Anne T Gelderloos, Daniella RAI Berry, Nathalie J Hijmering, Daphne de Jong, Martine E.D. Chamuleau, Sonja Zweegman, Esther CW Breij, Margaretha GM Roemer, Tuna Mutis
Journal: Blood (2019)
Apremilast in Treatment-Refractory Recurrent Aphthous Stomatitis
Authors: Antonios G A Kolios, Nikhil Yawalkar, Arlene Feusi, Thomas Kündig, Onur Boyman, Jakob Nilsson
Journal: New England Journal of Medicine (2019)

Apremilast for Treatment-Resistant Aphthous Ulcers Five patients with recurrent aphthous stomatitis were treated with apremilast, an oral phosphodiesterase-4 inhibitor that inhibits production of T...
Preliminary Results from a Multicenter, Single-Arm, Phase 2 Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb), in Patients (pts) with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (rr-ENKTL)
Authors: Hui-qiang Huang, Rong Tao, Liqun Zou, Hong Cen, Ye Guo, Yunhong Huang, Wenbin Qian, Liling Zhang, Hui Zhou, Yu Yang, Haiyan Yang, Dan Zhu, Teng Fang, Hangjun Dai, Yueling Wang, Jianxin Yang
Journal: Blood (2019)
The Necessary for Long-Term Follow-up of Mutated Genes and Clonal Evolutions in Multiple Myeloma Combined with cfDNA Assay
Authors: Yuko Mishima, Yuji Mishima, Masahiro Yokoyama, Noriko Nishimura, Yoshiharu Kusano, Norihito Inoue, Hideki Uryu, Takanori Fukuta, Yuko Shirouchi, Kiyohiko Hatake, Yasuhito Terui
Journal: Blood (2019)
The Unforeseen Medical and Business Challenges Found When Integrating Abstracted Data from Disparate EHR Systems While Building the Curecloud Direct-to-Patient Multiple Myeloma Registry
Authors: Steven E. Labkoff, Shaadi Mehr, Christopher Williams, Daniel Auclair, Paul A. Giusti, Kathy E. Giusti, Stuart L. Goldberg, Kevin M Keogh, Andrew J. Belli, Andrew D Norden
Journal: Blood (2019)
IMMU-39. RNA LOADED LIPID-NANOPARTICLES FUNCTION AS CUSTOMIZABLE IMMUNOTHERAPEUTIC VEHICLES AGAINST MALIGNANT GLIOMAS
Authors: Adam Grippin, Brandon Wummer, Hector Mendez-Gomez, Brian Stover, Jianping Huang, Carlos Rinaldi, Duane Mitchell, Jon Dobson, Elias Sayour
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND While dendritic cell (DC) vaccine therapy has shown considerable promise for glioblastoma (GBM) patients (Mitchell et al. Nature, 2015), their advancement into human clinical trials has been fraught with challenges in the development, manufacturing, and marketing of successful cancer immunotherapies. To circumvent the challenges associated with cell therapy, we have developed a new platform technology consisting of tumor derived mRNA complexed into lipid-nanoparticles (RNA-NPs) for systemic delivery to DCs in vivo and induction of antigen specific T cell immunity against GBM. OBJECTIVES/ METHODS We sought to assess if surface and charge modifications to our custom lipid-NP could facilitate its localization to lymphoid organs and the brain tumor microenvironment. RESULTS We demonstrate that intravenous administration of our unmodified custom RNA-NPs mediate systemic activation of DCs; these include activation of CD11c+ cells in the brains of animals with intact blood brain-barriers (BBBs). RNA-NPs mediate antigen specific T cell immunity and anti-tumor efficacy with increased tumor infiltrating lymphocytes against a NF-1/p53 mutant glioma that recapitulates features of human GBM in immunocompetent mice. Modification of surface charge could direct these RNA-NPs to lymphoid organs (e.g. spleen, lymph nodes) while modification of the lipid backbone (with cholesterol) enhances localization to innate immune cells in NF-1/p53 mutant and GL261 gliomas. We therefore assessed if this customizable lipid-NP could be leveraged for delivery of immune checkpoint inhibitors (ICIs) (i.e. PD-L1 siRNA) to the brain tumor microenvironment. Compared with scrambled siRNA-NPs in combination with ICIs, surface modified siRNA-NPs (antagonizing PD-L1) in combination with ICIs mediated significant antitumor efficacy with 37% long term survivors in an otherwise fatal brain tumor model. CONCLUSION We designed multifunctional RNA-NPs with a simple, scalable synthesis method that enables delivery of nucleic acids to innate immune cells in lymphoid organs and brain tumors.
PATH-37. PROGNOSTIC ROLE OF TERT PROMOTER MUTATIONS IMPROVES THE STRATIFICATION OF IDH-MUTATED LOWER GRADE GLIOMA
Authors: Hideyuki Arita, Yuko Matsushita, Makoto Ohno, Yohei Miyake, Kuniaki Saito, Shota Tanaka, Taishi Nakamura, Kaoru Tamura, Fumi Higuchi, Eriel Sandika, Hemragul Sabit, Yasuhiko Hattori, Shigeru Yamaguchi, Yoshiko Okita, Daisuke Sakamoto, Junya Fukai, Takehiro Uda, Nohuhiro Hata, Tomoko Shofuda, Takashi Sasayama, Kanji Mori, Kazuhiko Kurozumi, Masayuki Kanamori, Hikaru Sasaki, Haruhiko Kishima, Yonehiro Kanemura, Mitsutoshi Nakada, Yukihiko Sonoda, Motoo Nagane, Keisuke Ueki, Ryo Nishikawa, Yoshitaka Narita, Koichi Ichimura
Journal: Neuro-Oncology (2019)

Abstract TERT promoter mutation is associated with 1p/19q codeletion and favorable prognosis in IDH-mutated gliomas. Prognostic and diagnostic significance of TERT promoter mutation is well-recognized in IDH-wildtype glioblastomas, but not in IDH-mutated gliomas. We investigated prognostic efficacy of TERT mutation in a cohort of 560 Japanese IDH-mutated adult gliomas. The molecular status of IDH, TERT and 1p/19q and patient clinical data including Karnofsky performance status (KPS) were collected in all cases. TERT mutations and 1p/19q codeletions were found in 303 and 285 cases, respectively. The patient cohort was divided into four groups by a combination of the 1p/19q and TERT status. The characteristics of 1p/19q intact-TERT mutated group (Astro-TERT group, n=24) were compared with those of 1p/19q intact-TERT wild (Astro-group, n=251) or 1p/19q codeleted-TERT mutated (Oligo-group, n=279) cases. Astro-TERT group with any grade showed intermediate overall survival between the Oligo-group and Astro-group although the survival differences were not statistically significant (median overall survival (OS) not reached (NR) versus NR, and 106 months, respectively. p &gt;0.05). We further conducted subgroup analysis by adjusting KPS and WHO grade as Cox regression analysis for survival indicated the unfavorable survival impact of KPS &lt; 90 and WHO grade IV. In the subgroup with favorable KPS (90–100) and grade II-III (n=438), The OS of Astro-TERT group (median NR) was significantly longer survival than that of Astro-group (median 120.2 months, p=0.032), and was comparable with that of the Oligo-group (median NR, p &gt;0.05). On the other hand, OS of none of the molecular groups significantly differ in poorer KPS subgroups (p &gt;0.05). In grade IV tumors, the OS of the Astro-TERT group (NR) was comparable with that of Astro-group (29 months, p=0.19) rather than Oligo-group (NR, p=0.051). Thus, TERT promoter status provides a valuable prognostic information for IDH-mutated grade II-III gliomas in the current molecular diagnostic system.
Communication and management of incidental pathology in 1,214 consecutive appendicectomies; a cohort study
Authors: Ned Kinnear, Bridget Heijkoop, Eliza Bramwell, Alannah Frazzetto, Amy Noll, Prajay Patel, Derek Hennessey, Greg Otto, Christopher Dobbins, Tarik Sammour, James Moore
Journal: International Journal of Surgery (2019)
Combined stent-in-stent and side-by-side stenting for hilar cholangiocarcinoma using a novel braided and weaving metal stent
Authors: Tomotaka Saito, Sachiko Kanai, Tsuyoshi Hamada, Hirofumi Kogure, Yousuke Nakai, Kazuhiko Koike
Journal: Endoscopy (2019)

For hilar malignant biliary obstruction, bilateral self-expandable metal stent (SEMS) placement provides longer patency than unilateral drainage [1] [2]. Although recently developed fine-gauge delivery systems allow simultaneous side-by-side (SBS) placement, the partial stent-in-stent (SIS) method is sometimes preferred because of higher adverse event rates with SBS [3]. However, technical difficulty can be encountered with the SIS method, such as guidewire or stent delivery through the stent interstice [4]. Herein, we present a combined SIS and SBS technique using a novel SEMS with a combination of braided and weaving construction ([Video 1]).
Increased Frequency of Thromboses Among Patients with Philadelphia (Ph) Negative Myeloproliferative Neoplasms in New Mexico: The Role of Prothrombotic Risk Factors
Authors: Qiuying Selina Liu, Shashank Y. Cingam, Khine Z Win, Tawny Boyce, Cecilia Y. Arana Yi
Journal: Blood (2019)
ATIM-14. RESULTS OF PHASE II CLINICAL TRIAL OF ONCOLYTIC HERPES VIRUS G47Δ IN PATIENTS WITH GLIOBLASTOMA
Authors: Tomoki Todo
Journal: Neuro-Oncology (2019)

Abstract Genetically engineered, conditionally replicating herpes simplex viruses type 1 (HSV-1) are promising therapeutic agents for cancer. We have developed a triple-mutated, third-generation oncolytic HSV-1, G47∆, that exhibits enhanced replication capability in a variety of cancer, efficient induction of specific antitumor immunity, and high safety features. G47∆ also kills cancer stem cells very efficiently. The first-in-man, phase I-IIa study of G47∆ in recurrent glioblastoma patients was performed from 2009 to 2014 at the University of Tokyo, followed by phase II investigator-initiated clinical trial in patients with recurrent or residual glioblastoma from 2015 to test the efficacy. In this phase II, each patient received stereotactic injections with G47∆ into the tumor, repeatedly, but into different coordinates, every 4 weeks, for the maximum 6 times. A set dose of 1 x 10E9 pfu/dose was used. In most patients, G47∆ was given in addition to the maintenance chemotherapy using temozolomide. The primary endpoint was a 1-year survival rate. The repeated stereotactic injections were well tolerated. The interim analysis showed that the 1-year survival rate of 13 patients was 92.3%, which was significantly higher than 15%, the preset control value based on meta-analysis of historical data. The statistical significance was above the criteria of early termination, so this trial was terminated early and considered as the pivotal study for new drug application. Severe adverse events related to G47∆ were experienced by 2 patients only, both of which were grade 2 fever. Because G47∆ was designated as a ‘Sakigake’ breakthrough therapy drug by the Japanese government, and further as an orphan drug for malignant glioma, a fast-track drug approval is expected. G47∆ has proven safe even when injected repeatedly 6 times into the brain. The use of G47∆ may become a preferred treatment that potentially leads to a cure of malignant glioma in the near future.
A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma
Authors: Nina D. Shah, Cameron J. Turtle, Andrew J. Cowan, Julio C. Chavez, Lihua E Budde, Mario Q. Marcondes, Zachary Lee, Wei Lin, Jonathan Zalevsky, Mary Tagliaferri, Krina K. Patel
Journal: Blood (2019)
Clinical Evaluation of a Single-Use Duodenoscope for Endoscopic Retrograde Cholangiopancreatography
Authors: V. Raman Muthusamy, Marco J. Bruno, Richard A. Kozarek, Bret T. Petersen, Douglas K. Pleskow, Divyesh V. Sejpal, Adam Slivka, Joyce A. Peetermans, Matthew J. Rousseau, Gregory P. Tirrell, Andrew S. Ross
Journal: Clinical Gastroenterology and Hepatology (2019)
Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome: A Large Series from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Authors: Olivier Tournilhac, Romain Guièze, Dirk-Jan Eikema, Nienke Zinger, Henrik Sengeloev, Jakob R. Passweg, Bendt Nielsen, Xavier Poire, Jenny Byrne, Martin Gramatzki, Jürgen Finke, Jan J Cornelissen, D Blaise, Emmanouil Nikolousis, Patrice Chevallier, Gwendolyn Van Gorkom, Mark Ringhoffer, Nicola Mordini, Liesbeth C. de Wreede, Patrick John Hayden, Michel van Gelder, Ibrahim Yakoub-Agha
Journal: Blood (2019)
Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinases Exerts Synergistic Effect Against Chronic Myeloid Leukemia Cells
Authors: Sylwia Flis, Ewelina Bratek, Tomasz Chojnacki, Marlena Piskorek, Tomasz Skorski
Journal: Blood (2019)